Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Viyash Scientific Limited (VIYASH.NS)
Hyderabad, IN
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.06% | +11.58% | +25.98% | +19.01% | +17.57% | +25.14% | +42.02% | +254.57% | -6.06% | +121.59% | +70.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+120.5% ★ Q1'26: +129.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+371.8% ★ Q1'26: +225.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.1% Q1'26: +3.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.3% Q1'26: +13.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.1% ★ Q1'26: +9.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+71.8% Q1'26: +72.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.75× Q1'26: 0.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
13.66B
est: 15.31B (-10.7%)
|
15.51B
est: 14.74B (+5.2%)
|
33.72B
33.59B – 33.86B
+128.7% YoY
|
39.17B
39.00B – 39.33B
+16.1% YoY
|
44.21B
43.37B – 45.04B
+12.9% YoY
|
| EBITDA |
549.80M
est: 1.06B (-48.1%)
|
1.59B
est: 1.13B (+40.0%)
|
2.60B
2.59B – 2.61B
+128.7% YoY
|
3.01B
3.00B – 3.03B
+16.1% YoY
|
3.40B
3.34B – 3.47B
+12.9% YoY
|
| EBIT |
-65.60M
est: 445.31M (-114.7%)
|
924.10M
est: 451.56M (+104.6%)
|
1.03B
1.03B – 1.04B
+128.7% YoY
|
1.20B
1.19B – 1.20B
+16.1% YoY
|
1.35B
1.33B – 1.38B
+12.9% YoY
|
| Net Income |
-358.69M
est: 463.34M (-177.4%)
|
218.80M
est: 2.08B (-89.5%)
|
3.01B
2.34B – 3.67B
+44.7% YoY
|
4.18B
4.02B – 4.33B
+39.0% YoY
|
5.88B
5.84B – 5.92B
+40.7% YoY
|
| SGA |
839.49M
est: 862.70M (-2.7%)
|
893.95M
est: 1.23B (-27.6%)
|
2.82B
2.81B – 2.83B
+128.7% YoY
|
3.28B
3.26B – 3.29B
+16.1% YoY
|
3.70B
3.63B – 3.77B
+12.9% YoY
|
| EPS |
-1.44
est: 1.80 (-180.0%)
|
0.88
est: 4.70 (-81.3%)
|
6.80
5.30 – 8.30
+44.7% YoY
|
9.45
9.10 – 9.80
+39.0% YoY
|
13.30
13.20 – 13.40
+40.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.05% | 224.1K | 0.49% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 257.5K | 0.65% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.03% | 4.63M | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajaram Narayanan | MD, Chief Executive Officer & Director | 20M | male |
| Ramakant Singani | Chief Financial Officer | 15M | male |
| Phillip Trott | Assoc. Vice President, Head of Legal & Chief Risk Officer | 8M | male |
| Yoshita Vora | Company Secretary & Compliance Officer | 3M | female |
| Prasad Lad | Vice President of HR & Administration | — | male |
| Ramesh Kumar Pillai | Corporate Vice President of Ra Qa and Technical Services | — | male |
| Ravi Nair | Executive Vice President of Human Resources & Administration | — | male |
| Srinivas Vasireddy | Executive Director | — | male |
| Abhishek Singhal | Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIYASH.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
